3 Reasons This Recent IPO Is Ready to Take Off

MAV Beauty Brands (TSX:MAV) went public July 10 at $14 a share. It’s yet to trade above its IPO price. That’s about to change.

| More on:
soar high in the sky

MAV Beauty Brands (TSX:MAV) is projecting 25% annual sales growth over the next three years, yet it’s been unable to crack its $14 IPO price since going public July 10.

Marc Anthony Venere, the founder of MAV, has been a hairstylist to some of the biggest stars including Eva Longoria, as well as running his hair salon, but the personal care products have taken him to where he is today — the CEO of a business that’s projected to generate US$160 million in annual revenue by 2020.

Before MAV Beauty went public, I discussed the five things investors needed to understand before buying its stock.

While I liked the idea of a Canadian beauty products business going public, I thought investors were better off buying Estee Lauder (NYSE:EL) at four times sales than paying six times sales for a company that’s not nearly as established.

That said, I was thinking of the average investor who can’t afford to lose their investment, but if you’re an aggressive investor who doesn’t mind a little risk, MAV stock isn’t a terrible bet.

Here are three reasons why.

U.S. expansion should do wonders

One of MAV Beauty’s strategies for growth is to conquer the U.S. market. And while many investors snicker whenever a Canadian company proclaims it’s going to take Manhattan so to speak, I think the company’s plan is a good one.

MAV Beauty has three major brands: Marc Anthony (the original), Cake and Renpure (acquisitions). Right now in the U.S., MAV Beauty has 47 retailers carrying its products. However, 36 of those retailers carry just one of the three brands. Canaccord Genuity Group analyst Camilo Lyon believes getting more of the brands in each of the stores could be worth $36 million in revenue over the next three years.

Of those retailers, 67% of its revenue is from large drug-store chains such as Shoppers Drug Mart in Canada and CVS Health (NYSE:CVS) in the U.S. If MAV can branch out beyond the most obvious candidates, it can build its sales base south of the border.

Innovation is in its DNA

Venere is all about innovation and speed to market. According to the CEO, MAV Beauty gets new products to market in 3-6 months compared to 2-3 years for companies like Estee Lauder.

Millennials and other young consumers want products that are timely and customized to their specific needs. Like the trend to fast fashion, consumers want it now, and if one company can’t meet their needs, they’ll find one that can.

I don’t know if Ulta Beauty sells any of the company’s products yet, but having an innovation mindset should help it gain counter space.

Analysts like it

All five analysts who cover MAV Beauty’s stock have a buy on it with an average 12-month target price of $17.50 with Camilo Lyon giving it a $22 target, 65% higher than where it trades today.

In the second quarter ended June 30, 2018, MAV Beauty had revenue of US$22.9 million, 36% higher than a year earlier; its adjusted profit was US$3.2 million, 35% higher than in the same period a year ago.

Revenues were higher as a result of greater penetration in the North American market. It expects total revenue of US$81.4 million in fiscal 2018, representing 19% growth year over year. On the profit front, it expects adjusted EBITDA of US$27 million in 2018, 10% higher than in 2017.

The verdict on MAV Beauty

I wasn’t ready to recommend MAV stock back in early July, but I’m starting to take a shine to it. If you’ve got some funds set aside for speculative bets that you can afford to lose, MAV Beauty’s stock looks like it’s ready to launch.

 

Fool contributor Will Ashworth has no position in any stocks mentioned.

More on Investing

A modern office building detail
Dividend Stocks

2 Canadian REITs That Look Worth Buying Right Now

SmartCentres REIT (TSX:SRU.UN) and another yield-rich, passive-income play are fit for Canadian value seekers.

Read more »

man looks surprised at investment growth
Investing

3 Canadian Stocks That Look Undervalued and Worth Buying Right Now

These high-quality Canadian stocks still look undervalued and are well-positioned to deliver notable growth in the future.

Read more »

dividends grow over time
Investing

3 Canadian Growth Stocks Worth Adding to a TFSA This Year

Three Canadian growth stocks are valuable additions to the TFSA for investors prioritizing capital gains over dividend income in 2026.

Read more »

crisis concept, falling stairs
Stocks for Beginners

2 Canadian Stocks That Could Utterly Destroy a $100,000 Portfolio

Understand the risks associated with goeasy stock and its significant decline. Protect your portfolio with informed decisions.

Read more »

man gives stopping gesture
Dividend Stocks

2 Stocks That Canadian Retirees May Want to Think Twice About Owning

If you have a long investment horizon and a portfolio geared for retirement planning, these two stocks are investments you…

Read more »

senior man smiles next to a light-filled window
Dividend Stocks

3 Dividend Stocks to Buy if Rates Stay Higher for Longer

Higher rates make yield traps more dangerous, so these three dividend names show three different “quality income” approaches.

Read more »

middle-aged couple work together on laptop
Dividend Stocks

5 Canadian Stocks Beginners Can Buy and Hold Forever

These five Canadian stocks offer beginners a mix of simple business models and long-term staying power.

Read more »

Income and growth financial chart
Dividend Stocks

1 Canadian Stock I’d Buy Before Trade Tensions Heat Up Again

Trade tensions can rattle markets, but food companies like Maple Leaf tend to hold steadier because people still need to…

Read more »